DIA第五届中国年会 PATIENT SAFETY TOP OF AGENDA AT THE 5TH DIA CHINA ANNUAL MEETING

Patient Safety – A Sustained Focus from Scientific Ideas to Innovative Medicines – will be the main 

theme for discussion when pharmaceutical and health care professionals from around the world meet for

 the 5th DIA China Annual Meeting.

The 5th DIA China Annual Meeting, co-sponsored by the China Center for Pharmaceutical International

Exchange (CCPIE) of the China Food and Drug Administration (CFDA), will be held at the Beijing 

International Convention Center from May 12 to 15. 

The meeting, featuring more than 40 sessions and 60 exhibitors, will bring together professionals from the 

pharmaceutical and biopharmaceutical industries, contract research and service organizations, regulatory

 agencies and academic institutes on a neutral global platform. Attendees will share knowledge and 

experience focusing on better public health protection, patient benefits, best practices and compliance in 

alignment with science and regulations.

Program Co-chair Dr Lingshi TAN, Vice President, Pfizer Worldwide Development Operations, said: “The 

China Annual Meeting helps to enhance communication and collaboration between China and the world. 

This year’s sessions will highlight the latest developments within the pharmaceutical industry in China, 

explore ideas that will impact global health, and feature open debates among senior professionals, top 

academics, and high-level officials from various fields in medicine development. Patient safety will be 

reinforced as a core element of therapeutic innovation and a key philosophy throughout the life cycle of

 pharmaceutical and biopharmaceutical management.”

Program Co-chair Yajun ZHAO, Director-General, China Center for Pharmaceutical International 

Exchange, SFDA, said: “Drug safety is the pivotal mission of China’s drug regulatory agencies and will be

the main theme of the DIA China Annual Meeting, alongside patient care. The China Annual Meeting will 

be an extraordinary platform for exchange between drug regulatory agencies, industry, and academic 

institutes exploring ideas to ensure drug safety and protect people’s health.”

The key themes include:

·         Chemistry, Manufacturing and Controls (CMC)

·         Clinical Research and Operations

·         Data Management

·         Drug Safety and Pharmacovigiliance

·         Regulatory Science

·         Statistics

·         Clinical Services Organization – Opportunities in China 

·         Vaccine and Biologics

New themes and topics include: 

·         CFDA Townhall Meeting 

·         Regulatory and Drug Safety Joint Program: Balancing Risk and Benefit during NDA and Post-Marketing Periods

·         Botanical Drug Products in China and the United States 

·         Future Oncology Drug Development: Opportunities and Challenges 

·         Pharmacoepidemiology – Best Practices and Drug Safety

·         Pharm/Tox

·         Post-approval and Real World Studies 

·         Development of Novel Traditional Chinese Medicines (TCM) for China and Global Markets 

For more information about the China Annual Meeting or to register, visit www.diachina.org

There is a group discount available when registering. Call the DIA China Office on +86.10.6260.2240 or 

email dia@diachina.org for more details.

Companies interested in exhibition, hosting opportunities, and advertisements at the 5th China Annual 

Meeting email jxu@kellencompany.com

ABOUT DIA www.diahome.org

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved 

in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical 

devices and related health care products. Through our international educational offerings and myriad 

networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation 

of products, technologies and services to improve health and well being worldwide. Headquarters are in 

Horsham, PA. USA, with offices in Washington DC, USA, Basel, Switzerland, Tokyo, Japan, Mumbai, 

India and Beijing, China. 

DIA第五届中国年会

2013年5月12-15日
中国 北京·北京国际会议中心

DIA第五届中国年会将围绕“患者关爱与药物安全”的主题，于2013年5月

12-15日在北京国际会议中心隆重召开。中国年会是DIA在中国及亚太地区每年

举办的规模最大的会议之一。

药物安全是当前监管部门和企业界所关注的话题。随着中国社会经济的快速发展，

科技的不断进步，创新药物和治疗手段的不断更新和使用，如何正确认识药物风

险、增强公众用药安全意识、普及医药科学知识，有效管理风险，乃是21世纪

全球所面临的挑战。

本届年会将有来自国内外新药研发机构、临床基地、科研院所、生产厂家以及药

监部门等知名学者、专家、企业家代表，政府官员和媒体参加。届时，来宾将围

绕年会主题，共同讨论和探讨业界当前热点话题，并展望中国和世界制药发展的

前景和趋势。 

本次大会设有精彩主题演讲、14个专题研讨的40多个分会场。形式包括分会场

报告、焦点论坛、会前专题研讨、壁报及医药展会。

会前专题研讨

l  运用数据分析技术实现临床研究成果的监控和评估

l  原料药和制剂的稳定性要求与实践 

l  肿瘤临床试验中的数据管理 

l  从药物监管角度看MedDRA(ICH国际医学用语词典)
在临床试验药物安全和药物警戒方面的应用 

l  全球性药物临床试验的原则与案例研究 

专题会场

l  临床研究与运行 

l  监管科学 

l  药物安全和药物警戒 

l  统计学 

l  疫苗和生物制品

l  CMC/cGMP 

l  传统中药创新

l  肿瘤靶向药物的研发 

l  药物毒理 

l  数据管理和电子临床 

l  医疗器械及药械组合产品的创新 

l  合同研究机构 

l  药物流行病的最佳实践和药物安全  

l  上市后和实际环境中的药物研究 

会议日程

详情请联系DIA中国办公室： 
电话: +86-10-6260-2240
邮箱: dia@diachina.org

展览机会

l  展位

l  会刊手册广告

l  会议支持

l  展商研讨会 

联系人：徐迎宾 女士
电话：+86.10.5923.1096 传真：+86.10.5923.1090
邮箱：jxu@kellencompany.com

首页： http://www.eventdove.com/s/1722

注册： http://www.eventdove.com/c/1722/m/3716